Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today three new investments from the Sofinnova Telethon Fund, its early-stage fund dedicated to investments in rare, genetic diseases. The startups, AAVantgarde Bio, Alia Therapeutics, and Borea Therapeutics, are developing promising new therapies for rare, genetic diseases.

Julier is developing a next generation mechanical thrombectomy solution for the removal of thrombus and revascularization of patients experiencing Acute Ischemic Strokes. The core technology is derived from the work of two serial medtech entrepreneurs, Laurent Grandidier and Niall Behan. 

http://juliermedical.com/

Medical Device

Medical

Sofinnova Partners Announces Three New Investments From Its Fund Dedicated To Italian Scientific Research

Description

Company Information

Related People

Sofinnova Partners Announces Three New Investments From Its Fund Dedicated To Italian Scientific Research

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Company Information